The estimated Net Worth of Vincent T Marchesi is at least $5.09 Millón dollars as of 14 May 2021. Vincent Marchesi owns over 40,000 units of Exelixis Inc stock worth over $2,825,842 and over the last 22 years he sold EXEL stock worth over $1,807,309. In addition, he makes $455,227 as Independent Director at Exelixis Inc.
Vincent has made over 17 trades of the Exelixis Inc stock since 2002, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of EXEL stock worth $252,000 on 14 May 2021.
The largest trade he's ever made was selling 61,683 units of Exelixis Inc stock on 15 January 2020 worth over $1,234,277. On average, Vincent trades about 11,437 units every 179 days since 2002. As of 14 May 2021 he still owns at least 106,115 units of Exelixis Inc stock.
You can see the complete history of Vincent Marchesi stock trades at the bottom of the page.
Dr. Vincent T. Marchesi M.D. Ph.D. serves as Independent Director of the Company. Vincent T. Marchesi, M.D., Ph.D., has been a director since May 2001. Since 1973, Dr. Marchesi has been a Professor of Pathology and Cell Biology at Yale University and, since 1991, the Director of the Boyer Center for Molecular Medicine at Yale University. In 1982, Dr. Marchesi co-founded Molecular Diagnostics, Inc., a diagnostic development company. Dr. Marchesi was formerly Chair of Pathology at the Yale-New Haven Hospital. Dr. Marchesi holds an M.D. from Yale University and a Ph.D. from Oxford University, and is a member of the National Academy of Sciences and the Institute of Medicine.
As the Independent Director of Exelixis Inc, the total compensation of Vincent Marchesi at Exelixis Inc is $455,227. There are 13 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
Vincent Marchesi is 84, he's been the Independent Director of Exelixis Inc since 2001. There are no older and 21 younger executives at Exelixis Inc.
Vincent's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 22 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey y Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: